ERBB2 and cancer: Subsequently, in support of the above data, Gong and colleagues demonstrated that the treatment of HER2+ epirubicin-resistant SKBR3 cells and adriamycin-resistant luminal A MCF7 cells with lapatinib or salinomycin, an inhibitor of oxidative phosphorylation (OXPHOS) that efficiently targets both CSCs and therapy-resistant cancer cells, significantly reduced the MFE by approximately 10–100-fold in the CD44high/CD24low BCSC subset and, in parallel, decreased the percentage of ALDH+ cells, enhancing the sensitivity of BC cells to chemotherapy by approximately 30-fold [76].